Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure.
Angiotensin-converting enzyme 2 (ACE2) has been suggested to be involved in the central regulation of autonomic function. During chronic heart failure (CHF), elevated central angiotensin II signaling contributes to the sustained increase of sympathetic outflow. This is accompanied by a downregulation of ACE2 in the brain. We hypothesized that central overexpression of ACE2 decreases sympathetic outflow and enhances baroreflex function in CHF. Transgenic mice overexpressing human ACE2 selectively in the brain (SYN-hACE2 [SA]) and wild-type littermates (WT) were used. CHF was induced by permanent coronary artery ligation. Four weeks after coronary artery ligation, both WT and SA mice exhibited a significant decrease in left ventricular ejection fraction (<40%). A slight decrease in mean arterial pressure was found only in SA mice. Compared with WT mice with CHF, brain-selective ACE2 overexpression attenuated left ventricular end-diastolic pressure; decreased urinary norepinephrine excretion; baseline renal sympathetic nerve activity (WT CHF: 71.6±7.6% max versus SA CHF: 49.3±6.1% max); and enhanced baroreflex sensitivity (maximum slope: WT sham: 1.61±0.16%/mm Hg versus SA CHF: 1.51±0.17%/mm Hg). Chronic subcutaneous blockade of mas receptor increased renal sympathetic nerve activity in SA mice with CHF (A779: 67.3±5.8% versus vehicle: 46.4±3.6% of max). An upregulation in angiotensin II type 1 receptor expression was detected in medullary nuclei in WT CHF mice, which was significantly attenuated in SA mice with CHF. These data suggest that central ACE2 overexpression exerts a potential protective effect in CHF through attenuating sympathetic outflow. The mechanism for this effect involves angiotensin (1-7) mas signaling, as well as a decrease in angiotensin II type 1 receptor signaling in the medulla.
Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198-5850, USA.
Liang
L
Xiao
Lie
L
Gao
Eric
E
Lazartigues
Irving H
IH
Zucker
D000803:Angiotensin I / Q000494:pharmacology; D000804:Angiotensin II / Q000031:analogs & derivatives / Q000494:pharmacology; D000085962:Angiotensin-Converting Enzyme 2; D000818:Animals; D017704:Baroreflex; D004790:Enzyme Induction; D006333:Heart Failure / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008526:Medulla Oblongata / Q000503:physiopathology*; D051379:Mice; D018345:Mice, Knockout; D017202:Myocardial Ischemia / Q000150:complications; D009419:Nerve Tissue Proteins / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology; D009638:Norepinephrine / Q000652:urine; D009928:Organ Specificity; D010446:Peptide Fragments / Q000494:pharmacology; D007703:Peptidyl-Dipeptidase A / Q000235:genetics / Q000502:physiology*; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000172:deficiency / Q000187:drug effects; D011945:Receptors, Angiotensin / Q000096:biosynthesis; D043562:Receptors, G-Protein-Coupled / Q000096:biosynthesis / Q000172:deficiency / Q000187:drug effects; D011993:Recombinant Fusion Proteins / Q000502:physiology; D012021:Reflex, Abnormal; D013564:Sympathetic Nervous System / Q000503:physiopathology*
C092006:7-Ala-angiotensin (1-7); D009419:Nerve Tissue Proteins; D010446:Peptide Fragments; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D011945:Receptors, Angiotensin; D043562:Receptors, G-Protein-Coupled; D011993:Recombinant Fusion Proteins; D000804:Angiotensin II; D009569:Nitric Oxide; D000803:Angiotensin I; D007703:Peptidyl-Dipeptidase A; C000705307:ACE2 protein, human; C000705328:Ace2 protein, mouse; D000085962:Angiotensin-Converting Enzyme 2; C118790:angiotensin I (1-7); D009638:Norepinephrine